Moreover, the antiproliferative RNR inhibitor MB and the proapoptotic Bcl-2 inhibitor ABT-737 generate a synergistic therapeutic effect on AML cells, suggesting that rational combination treatment may also exert synergistic effects on other malignancies. This evidence concerns the gene BCL2 and acute myeloid leukemia.